|
![]() |
|
|
Cefadroxil: profile and news
Antibiotics keep blood bacteria-free Sep 27, 2005 Other information Indication For the treatment of the following infections (skin, UTI, ENT) caused by; S. pneumoniae, H. influenzae, staphylococci, S. pyogenes (group A beta-hemolytic streptococci), E. coli, P. mirabilis, Klebsiella sp, coagulase-negative staphylococci and Staphylococcu Pharmacology Cefadroxil, a first-generation cephalosporin antibiotic, is used to treat urinary tract infections, skin and skin structure infections, pharyngitis, and tonsillitis. Mechanism Of Action Like all beta-lactam antibiotics, cefadroxil binds to specific penicillin-binding proteins (PBPs) located inside the bacterial cell wall, causing the inhibition of the third and last stage of bacterial cell wall synthesis. Cell lysis is then mediated by bacterial cell wall autolytic enzymes such as autolysins; it is possible that cefadroxil interferes with an autolysin inhibitor. Drug Category Anti-bacterial Agents; Cephalosporins; ATC:J01DB05 Brand Names/Synonyms Baxan; Bidocef; CDX; Cefa-Drops; Cefadroxil; Cefadroxil Micronised Powder; Cefadroxil Monohydrate; Cefamox; Ceforal; Cefradroxil; Cephos; Duracef; Duricef; Kefroxil; Oracefal; Sedral; Sumacef; Ultracef Dosage Forms Cefadroxil comes as a capsule, tablet, and liquid to take by mouth Absorption Cefadroxil is well absorbed on oral administration; food does not interfere with the absorption Interactions -->Interactions for Cefadroxil: Drug/Laboratory Test Interactions Positive direct Coombsí tests have been reported during treatment with the cephalosporin antibiotics. In hematologic studies or in transfusion cross-matching procedures when anti-globulin tests are performed on the minor side or in Coombsí testing of newborns whose mothers have received cephalosporin antibiotics before parturition, it should be recognized that a positive Coombsí test may be due to the drug. Chemical IUPAC Name 8-[2-amino-2-(4-hydroxyphenyl)-acetyl]amino-4-methyl-7-oxo-2-thia-6-azabicyclo[4.2.0]oct-4-ene-5-carboxylicacid Chemical Formula C16H17N3O5S Half Life 1.5 h Drug Type Approved Drug # Accession No APRD00196 CAS Registry Number 66592-87-8 |
|
Home | About | Cancers | Treatment | Medications Copyright onconews.org 2005. All Rights Reserved. |